access to bispecifics and car-ts for multiple myeloma in brazil
Published 3 months ago • 27 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:57
disparities in access to car-t and bsab therapy for multiple myeloma
-
1:31
integrating bcma-directed bispecifics and car-t into the myeloma treatment landscape
-
3:44
clinical advances with car-ts and bispecifics in r/r myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:10
mechanisms of resistance to car t-cells in myeloma & future considerations
-
1:38
how to optimize access to car-t cell therapies in multiple myeloma
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
2:14
a new classification for identifying high-risk myeloma based on cytogenetic abnormalities
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
1:15
how bcma targeting bispecific antibodies may impact the subsequent use of car-t therapy in myeloma
-
3:24
approved and emerging car-ts in multiple myeloma
-
2:01
bite and car-t combinations for myeloma
-
4:11
expanding access to stem cell transplantation & car-t therapy in latin america
-
2:22
combining car-ts & bispecific antibodies
-
2:35
latest advances in car-t for multiple myeloma: cilta-cel & new car-t platforms
-
1:37
the use of bispecifics and car t-cells in south america: challenges that remain
-
1:45
car t-cells in myeloma: patients’ perspective